On April 23, 2025 Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, reported that pre-clinical data for IOV-5001, a genetically engineered, inducible, and tethered interleukin-12 (IL-12) TIL cell therapy, will be presented at the 2025 AACR (Free AACR Whitepaper) Annual Meeting (Press release, Iovance Biotherapeutics, APR 23, 2025, View Source [SID1234652057]). In addition, five-year outcomes data from the C-144-01 study of lifileucel monotherapy in patients with advanced melanoma, and a poster on study design for lifileucel in frontline advanced non-small cell lung cancer, will be presented at the 2025 ASCO (Free ASCO Whitepaper) Annual Meeting.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
2025 AACR (Free AACR Whitepaper) Annual Meeting, April 25-30, 2025, Chicago, IL
Poster: IOV-5001, autologous tumor-infiltrating lymphocytes armored with inducible membrane-tethered interleukin-12, shows enhanced antitumor efficacy with an improved cellular state (Abstract 4863)
Session: Immune Fitness and Metabolic Regulation of Cancer Immunity, Tuesday, April 29, 2025, 9:00 am – 12:00 pm CDT
2025 ASCO (Free ASCO Whitepaper) Annual Meeting, May 30-June 3, 2025, Chicago, IL
Rapid Oral Presentation: Lifileucel in patients with advanced melanoma: 5-year outcomes of the C-144-01 study (Abstract 9515)
Session: Melanoma/Skin Cancers, Monday, June 2, 2025, 9:45 am – 11:15 am CDT
Trial-in-Progress Poster: Phase 2, multicenter study of the lifileucel regimen and pembrolizumab after frontline platinum-doublet chemotherapy and pembrolizumab in advanced non-small cell lung cancer (Abstract 133A)
Session: Lung Cancer—Non-Small Cell Metastatic, Saturday, May 31, 2025, 1:30 pm – 4:30 pm CDT
Iovance will host a panel discussion on the evening of Saturday, May 31, 2025 at 6 pm CDT (7 pm EDT) featuring key opinion leaders in melanoma. The live and archived webcast will be available in the Investors section of the company’s website at www.iovance.com.